Orchestra BioMed (NASDAQ:OBIO) Stock: Insider Eric Fain Acquires 20,000 Shares

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Director Eric Fain purchased 20,000 shares of the firm’s stock in a transaction that occurred on Monday, November 9th. The stock was purchased at an average price of $5.00 per share, with a total value of $100,000.00. Following the completion of the purchase, the director directly owned 119,630 shares of the company’s stock, valued at approximately $598,150. This represents a 20.07% increase in their position. The purchase was disclosed in a filing with the SEC, which is available through the SEC website.

Orchestra BioMed Price Performance

Shares of Orchestra BioMed stock opened at $5.73 on Wednesday. The business has a 50-day moving average price of $5.77 and a 200 day moving average price of $4.59. Orchestra BioMed Holdings, Inc. has a fifty-two week low of $3.46 and a fifty-two week high of $6.50. The company has a debt-to-equity ratio of 1.80, a current ratio of 8.26 and a quick ratio of 8.24.

Orchestra BioMed (NASDAQ:OBIO) last released its earnings results on Tuesday, November 10th. The company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.10. Orchestra BioMed had a negative return on equity of 149.61% and a negative net margin of 184.60%. The company had revenue of $0.09 million for the quarter, compared to the consensus estimate of $0.13 million. On average, analysts predict that Orchestra BioMed Holdings, Inc. will post -1.53 EPS for the current fiscal year.

Hedge Funds Weigh In On Orchestra BioMed

A number of hedge funds and other institutional investors have recently bought and sold shares of OBIO. BlackRock Inc. bought a new position in shares of Orchestra BioMed during the second quarter valued at approximately $10,832,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in shares of Orchestra BioMed during the 2nd quarter worth approximately $2,771,000. Rice Hall James & Associates LLC bought a new stake in shares of Orchestra BioMed in the 2nd quarter worth approximately $1,830,000. Knott David M Jr lifted its holdings in shares of Orchestra BioMed by 1.5% in the 1st quarter. Knott David M Jr now owns 253,651 shares of the company’s stock worth $1,078,000 after purchasing an additional 3,651 shares during the last quarter. Finally, Flat Footed LLC bought a new stake in shares of Orchestra BioMed in the 2nd quarter worth approximately $1,084,670. 53.20% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms recently issued reports on OBIO. HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Orchestra BioMed in a research report on Monday, October 5th. Piper Sandler restated an “overweight” rating on shares of Orchestra BioMed in a research note on Thursday, October 15th. B. Riley Financial lifted their price objective on shares of Orchestra BioMed from $10.00 to $11.00 and gave the stock a “buy” rating in a report on Tuesday, September 15th. Chardan Capital reiterated a “buy” rating and set a $20.00 target price on shares of Orchestra BioMed in a research note on Friday, October 23rd. Finally, Weiss Ratings upgraded shares of Orchestra BioMed from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, September 10th. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $13.17.

Key Stories Impacting Orchestra BioMed

Here are the key news stories impacting Orchestra BioMed this week:

• Positive Sentiment: The company said its BACKBEAT Global Pivotal Trial of AVIM Therapy completed enrollment with 349 patients, exceeding its target. It plans to submit primary-endpoint data for a late-breaking presentation at Heart Rhythm Society 2027, giving investors a future clinical milestone to watch. Company third-quarter results and business updates
• Positive Sentiment: Several executives and directors bought shares at $5 each on November 9. Purchases included 20,000 shares each by directors David Pacitti and Eric Fain, 5,000 by David Hochman, and 1,000 by CFO Andrew Taylor. Insider buying can signal confidence, though it does not guarantee future performance. Insider purchase report
• Neutral Sentiment: OBIO reported a third-quarter loss of $0.30 per share, narrower than analysts’ expected $0.40 loss and the $0.40 loss a year earlier. However, revenue of $0.09 million missed the $0.13 million consensus estimate, tempering the earnings beat. Q3 earnings report

About Orchestra BioMed

Orchestra BioMed Holdings, Inc. is a clinical-stage biotechnology and medical device company focused on developing technologies for cardiovascular disease and other high-need medical conditions. The company uses a partnership-driven business model, collaborating with established medical device and healthcare companies to advance products through clinical development and toward commercialization. Its lead program is BackBeat Cardiac Neuromodulation Therapy, an investigational bioelectronic treatment intended to provide sustained reductions in blood pressure for patients with hypertension.